Onxeo is a biotechnology company, that develops drugs for the treatment of orphan oncology diseases worldwide. The Company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops Beleodaq for the treatment of others liquid or solid tumors; AsiDNA, which is in Phase I clinical trial for the treatment of metastatic melanoma; Livatag that is in Phase III clinical trial to treat advanced primary liver cancer; and Validive, which is in Phase II clinical trial for the treatment of serious mucositis in patients treated for a head and neck cancer.
Market capitalization (12-Feb-2021)
Closing stock price (12-Feb-2021)
Onxeo has 960 Twitter Followers. The number of followers has increased 0.2% month over month and increased 0.8% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Onxeo founded?
Onxeo was founded in 1997.
Who are Onxeo key executives?
Onxeo's key executives are Thomas Hofstaetter, Nicolas Trebouta and Jean-Pierre Bizzari.
How many employees does Onxeo have?
Onxeo has 30 employees.
Who are Onxeo competitors?
Competitors of Onxeo include Jiangsu Hansoh Pharmaceutical Group, 3sbio and Kyowa Kirin.
Where is Onxeo headquarters?
Onxeo headquarters is located at 49 Boulevard du Général Martial Valin, Paris.
Where are Onxeo offices?
Onxeo has offices in Paris, New York and København.
How many offices does Onxeo have?
Onxeo has 3 offices.
Receive alerts for 300+ data fields across thousands of companies